Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priyanka Samal

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|February 23, 2026
Indian College of Hematology (ICH)& Indian Council of Medical Research (ICMR) Joint Consensus Document on Management and Control of Sickle Cell Disease in IndiaRabindra Kumar Jena, Manoranjan Mahapatra, Tuphan Kanti Dolai, et al.
Cancer Chemotherapy and Pharmacology|April 24, 2023
Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in IndiaAnkit Patel, Niraj Bhatt, S S Prakash, et al.
Cancers|February 15, 2022
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL StudyJosée M Zijlstra, George Follows, Rene-Olivier Casasnovas, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 26, 2022
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL StudyMichael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.
Journal of Hematology & Oncology|July 17, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL studyMarie Maerevoet, Josee M Zijlstra, George Follows, et al.
Future Oncology (London, England)|February 2, 2021
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphomaJatin Shah, Sharon Shacham, Michael Kauffman, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|August 14, 2023
IMPETUS Stroke: Assessment of hospital infrastructure and workflow for implementation of uniform stroke care pathway in IndiaManish Salunkhe, Partha Haldar, Rohit Bhatia, et al.
Annals of Indian Academy of Neurology|March 28, 2022
Impact of the COVID-19 Pandemic on the Frequency, Clinical Spectrum and Outcomes of Pediatric Guillain-Barré Syndrome in India: A Multicentric Ambispective Cohort StudyDivyani Garg, Rajinder K Dhamija, Aditya Choudhary, et al.
Annals of Indian Academy of Neurology|March 13, 2023
Impact of COVID-19 on Guillain-Barre Syndrome in India: A Multicenter Ambispective Cohort StudyYareeda Sireesha, Ritu Shree, Madhu Nagappa, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|February 23, 2026
Indian College of Hematology (ICH)& Indian Council of Medical Research (ICMR) Joint Consensus Document on Management and Control of Sickle Cell Disease in IndiaRabindra Kumar Jena, Manoranjan Mahapatra, Tuphan Kanti Dolai, et al.
Cancer Chemotherapy and Pharmacology|April 24, 2023
Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in IndiaAnkit Patel, Niraj Bhatt, S S Prakash, et al.
Cancers|February 15, 2022
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL StudyJosée M Zijlstra, George Follows, Rene-Olivier Casasnovas, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 26, 2022
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL StudyMichael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.
Journal of Hematology & Oncology|July 17, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL studyMarie Maerevoet, Josee M Zijlstra, George Follows, et al.
Future Oncology (London, England)|February 2, 2021
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphomaJatin Shah, Sharon Shacham, Michael Kauffman, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|August 14, 2023
IMPETUS Stroke: Assessment of hospital infrastructure and workflow for implementation of uniform stroke care pathway in IndiaManish Salunkhe, Partha Haldar, Rohit Bhatia, et al.
Annals of Indian Academy of Neurology|March 28, 2022
Impact of the COVID-19 Pandemic on the Frequency, Clinical Spectrum and Outcomes of Pediatric Guillain-Barré Syndrome in India: A Multicentric Ambispective Cohort StudyDivyani Garg, Rajinder K Dhamija, Aditya Choudhary, et al.
Annals of Indian Academy of Neurology|March 13, 2023
Impact of COVID-19 on Guillain-Barre Syndrome in India: A Multicenter Ambispective Cohort StudyYareeda Sireesha, Ritu Shree, Madhu Nagappa, et al.
Pageof 6